Can mold mycotoxins promote mast-cell activation and histamine release?

Exposure to environmental mold mycotoxins is increasingly recognized for its complex immunological effects, which can have significant clinical implications.

Mast cell activation and histamine accumulation

• Direct Mast-Cell Degranulation: Specific mold mycotoxins, including ochratoxin A, gliotoxin, and trichothecenes, directly bind to mast cell surface receptors. This triggers rapid mast-cell activation and degranulation, releasing pre-stored and newly synthesized inflammatory mediators such as histamine, tryptase, prostaglandins, and leukotrienes.
• Impaired Histamine Degradation: Beyond promoting immediate histamine release, these mycotoxins suppress the production and activity of diamine oxidase (DAO)—the primary enzyme responsible for degrading extracellular histamine. This dual mechanism exacerbates systemic histamine accumulation and associated symptoms.

Impact on Type 2 immune polarization

• Compound-Specific Actions: The direct promotion of Type 2 (Th2) immune skewing is highly compound-specific rather than a universal effect. For example, the mycotoxin patulin has been shown in vitro to reduce key Th2 cytokines like IL-4 and IL-13, while zearalenone can inhibit IL-4 receptor-mediated Th2 cell differentiation.
• Indirect Polarization Pathway: Although direct Th2 skewing is variable, an indirect pathway is highly plausible. Mycotoxin-induced mast-cell activation triggers the release of various cytokines and immunomodulatory molecules, which can subsequently influence downstream T-cell polarization toward a Th2 phenotype.

Bottom line

• Mold mycotoxins directly drive mast-cell activation, histamine release, and impaired histamine degradation via DAO suppression. However, their influence on Type 2 immune skewing is complex and compound-specific, operating primarily as a plausible indirect consequence of the downstream mast-cell inflammatory cascade.